Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer

Bo Young Ahn1, Adam N. Elwi1, Byoungchun Lee1, Diane L.N. Trinh1, Alexander C. Klimowicz2, Annie Yau2, Jennifer A. Chan3,5, Anthony Magliocco2,3, and Sung-Woo Kim1,4,5

Abstract
Tamoxifen resistance is one of the overarching challenges in the treatment of patients with estrogen receptor (ER)–positive breast cancer. Through a genome-wide RNA interference screen to discover genes responsible for tamoxifen resistance in vitro, we identified insulin-like growth factor binding protein 5 (IGFBP5) as a determinant of drug sensitivity. Specific knockdown of IGFBP5 by retroviral infection with short hairpin RNA-expressing cassette in MCF7 human breast cancer cells (pRS-shIGFBP5) conferred tamoxifen resistance in vitro due to concomitant loss of ErbA expression and signaling. IGFBP5 expression was also reduced in MCF7 cells selected for tamoxifen resistance in culture (TAMR). Both tamoxifen-resistant MCF7-TAMR and MCF7-pRS-shIGFBP5 cells could be resensitized to drug by treatment with exogenous recombinant IGFBP5 (rIGFBP5) protein. Treatment with rIGFBP5 protein in mouse tumor xenografts reversed the in vivo tamoxifen resistance of MCF7-pRS-shIGFBP5 cell–derived tumors by reducing tumor cell proliferation. IGFBP5 immunohistochemical staining in a cohort of 153 breast cancer patients showed that low IGFBP5 expression was associated with shorter overall survival after tamoxifen therapy. Thus, IGFBP5 warrants investigation as an agent to reverse tamoxifen resistance. Cancer Res; 70(8); 3013–9. ©2010 AACR.

Introduction
Tamoxifen, a selective estrogen receptor (ER) modulator, is the most widely used chemotherapeutic in the treatment of ER-positive breast cancer (1). In spite of this, intrinsic and acquired resistance remains the main challenge to effective treatment with tamoxifen (2).

Antitumor effects of tamoxifen are mediated by competitive inhibition of estrogen binding to ERs (3), resulting in inhibition of estrogen-regulated genes including growth and angiogenic factors and cell cycle arrest (4) or induction of programmed cell death (5). ER loss of expression, mutation, and phosphorylation, overexpression of growth factor receptors [epidermal growth factor receptor, human epidermal growth factor receptor 2, and phosphorylation, overexpression of growth factor receptors [epidermal growth factor receptor, human epidermal growth factor receptor 2, and insulin-like growth factor receptor 1 (IGF-R1)], and activation of their downstream effectors [Akt/PKB, extracellular signal–regulated kinase (ERK)-1/2, and p38] and adaptors (Cas, c-Src, and BCAR-3) have been reported to be associated with tamoxifen resistance (2). Nevertheless, underlying mechanisms are poorly understood and few strategies have found success in the clinic in circumventing tamoxifen resistance. Therefore, the identification of new genes involved in tamoxifen resistance is an essential step toward improving breast cancer patient survival.

We performed an unbiased loss-of-function genetic screen on MCF7 human breast cancer cells using a short hairpin RNA (shRNA) library that identified insulin-like growth factor binding protein 5 (IGFBP5) as a modulator of tamoxifen sensitivity in vivo, thus revealing a new strategy for reversal of tamoxifen resistance.

Materials and Methods

Materials. MCF7 cells (American Tissue Culture Collection) were cultured in DMEM supplemented with 10% fetal bovine serum. Tamoxifen-resistant MCF7 cells (MCF7-TAMR) were derived by culturing for 4 wk in 10 μmol/L trans-4-hydroxytamoxifen (6). pRetroSuper (pRS; Origene)-infected and pRS vector expressing shRNA for IGFBP5 knockdown (pRS-shIGFBP5)–infected MCF7 cells (MCF7-pRS and MCF7-pRS-shIGFBP5, respectively) were maintained in media with 1.0 μg/mL puromycin.

shRNA library screening. Three shRNA oligonucleotides against each of 8,000 genes were designed and cloned into retroviral vector (pRS) containing a shRNA expression cassette (7). MCF7 cells were infected with pRS-shRNA library or pRS or mock infected, selected with puromycin (1.0 μg/mL) for 2 wk, and cultured in the presence or absence of tamoxifen (5 μmol/L).
6 d, genomic DNA was isolated and shRNA inserts were re-cloned into pRS. Screening was done for two additional rounds. Targeted genes were identified by sequencing shRNA inserts.

Reverse transcription-PCR. RNA was isolated, cDNA was synthesized, and PCR was done using IGFBP5- and ERα-specific primers (Supplementary Table S1).

Cell viability assays. Cell viability was measured using the WST1 assay (Roche Applied Science) or staining with 0.4% crystal violet.

Tumor formation assays. Animal experiments were done in accordance with the University of Calgary Animal Care Committee guidelines. Six-week-old athymic nu/nu CD female mice were implanted s.c. in the right flanks with 5 × 10^6 cells. Mice were injected i.m. with estradiol (E2 0.5 mg/kg per week) and s.c. with either tamoxifen (50 mg/kg per 2 wk) or PBS. Recombinant IGFBP5 (rIGFBP5; 20 μg) or PBS was systemically administered by tail vein injection.

Apoptosis assays. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were done using the In Situ Cell Death Detection Kit, TMR red (Roche Applied Science).

Immunohistochemistry. Ethics approval was obtained from the University of Calgary Institutional Review Board. Formalin-fixed, paraffin-embedded excised mouse tumor tissue sections were stained with IGFBP5 (Santa Cruz Biotechnology), cleaved caspase-3, or phosphohistone-H3 (Cell Signaling) antibodies. A tissue microarray containing 153 cases of pretreatment breast cancer biopsies from women treated with only tamoxifen therapy in Calgary between 1987 and 2000...
(Supplementary Table S2) was stained with anti-IGFBP5 antibodies. IGFBP5 was classified as either high or low expression based on evaluation of cytoplasmic expression level by pathologists blinded to outcome.

**Statistical analysis.** Single-group comparisons were done with two-tailed Student’s t tests. Overall survival was assessed using Kaplan-Meier survival curves with log-rank analysis and hazard ratio (HR) values were calculated using Cox proportional hazard model.

**Results**

**shRNA screen identifies genes involved in tamoxifen resistance.** Approximately 30% of ER-positive breast cancers do not respond to tamoxifen therapy and the majority that initially respond develop resistance despite continued ER expression (8, 9). The identification of new genes involved in drug resistance has been expedited by functional genetic screens (10). To identify new genes involved in tamoxifen resistance, a loss-of-function genetic screen was done. pRS-shRNA library or pRS stably infected MCF7 cells were cultured in the presence of tamoxifen (5 μmol/L) for 6 days, chosen because of drug sensitivity (Fig. 1A). Three successive rounds of screening led to the identification of shRNA for IGFBP5 (shIGFBP5), present in tamoxifen-resistant shRNA library–infected cells after each round (Fig. 1B) and for seven other genes under investigation. An increase in viability of shRNA library–infected cells was observed with 4- and 6-day tamoxifen treatments after second and third screenings, using WST1 (Fig. 1C) and crystal violet staining (Fig. 1D) assays. IGFBP5 is known to negatively regulate the IGF-I signaling pathway by inhibiting IGF-I interaction with IGF-IR (11). As IGF-I signaling is associated with aggressive phenotypes in breast cancer (11), IGFBP5 was chosen for further investigation.

**Exogenous rIGFBP5 reverses in vitro tamoxifen resistance induced by IGFBP5 suppression.** IGFBP5 mRNA transcripts were absent in MCF7-pRS-shIGFBP5 cells as compared with MCF7-pRS cells (Fig. 2A), leading to resistance to tamoxifen treatment in vitro (Fig. 2B). Tamoxifen-resistant MCF7-TAMR cells (6) also showed reduced IGFBP5 expression (Fig. 2D) associated with increased viability during tamoxifen treatment (Fig. 2D; Supplementary Fig. S1). As IGFBP5 is a secreted protein (11), we examined the possibility that exogenous treatment with rIGFBP5 could restore sensitivity to drug. In MCF7-pRS-shIGFBP5 (Fig. 2B) and MCF7-TAMR cells (Fig. 2C), treatment with 5 μg/mL rIGFBP5, chosen because of sensitivity (Supplementary Fig. S2), restored tamoxifen sensitivity. IGFBP5 and ERα expression is lost in MCF7-pRS-shIGFBP5 cells (Fig. 2A) regardless of tamoxifen and rIGFBP5 treatments (Supplementary Fig. S3). Whereas E2 and tamoxifen had no effect on IGFBP5 expression in MCF7-pRS or MCF7-pRS-shIGFBP5 cells (Supplementary Fig. S4), E2 attenuated reduction in viability of MCF7-pRS cells by tamoxifen (Supplementary Fig. S5) and induced phosphorylation of ERK1 in tamoxifen-treated or untreated

**Figure 2. IGFBP5 suppression induces tamoxifen resistance in vitro.** MCF7 cells were infected with pRS-shIGFBP5 or pRS (A and B) or selected for tamoxifen resistance (TAMR; C and D). Reverse transcription-PCR for IGFBP5 and ERα (A and C) and WST1 viability assays after 6 d in the presence or absence of tamoxifen (TAM; 5 μmol/L) with or without rIGFBP5 (5 μg/mL; B and D).
MCF7-pRS cells (Supplementary Fig. S6). On the other hand, downstream ER signaling was absent in E2- and tamoxifen-treated MCF7-pRS-shIGFBP5 cells (Supplementary Fig. S6). Therefore, suppression of IGFBP5 induces tamoxifen resistance, possibly through loss of ERα expression, whereas exogenous rIGFBP5 restores sensitivity to drug through a different mechanism.

**Exogenous rIGFBP5 reverses in vivo tamoxifen resistance induced by IGFBP5 suppression.** Whereas MCF7-pRS
cell–derived tumors showed significant decreases in tumor growth after tamoxifen treatments [Fig. 3A, a versus b; \( P < 0.05 \)], MCF7-pRS-shIGFBP5 cell–derived tumors, which had similar tumor growth to untreated MCF7-pRS cell–derived tumors (a versus d), showed no decrease in tumor growth after tamoxifen treatments as compared with untreated controls (d versus e) and had increased tumor growth after tamoxifen treatments as compared with tamoxifen-treated MCF7-pRS cell–derived tumors (e versus b, \( P < 0.05 \)). Treatment of MCF7-pRS cell–derived, but not of MCF7-pRS-shIGFBP5 cell–derived, tumors with rIGFBP5 alone resulted in a modest reduction in tumor growth (a versus c, d versus f; \( P < 0.05 \)). Cotreatment of MCF7-pRS-shIGFBP5 cell–derived tumors with tamoxifen and rIGFBP5 resulted in an additional reduction in tumor growth compared with tumors treated with rIGFBP5 alone (f versus g; \( P < 0.05 \)) and restored tamoxifen sensitivity of MCF7-pRS-shIGFBP5 cell–derived tumors compared with tumors treated with tamoxifen alone (e versus g; \( P < 0.05 \)). Similar to in vitro IGFBP5 expression (Supplementary Fig. S3), immunohistochemical staining for IGFBP5 in excised tumors led to confirmation of corresponding presence and absence of IGFBP5 in MCF7-pRS and MCF7-pRS-shIGFBP5 cell–derived tumors, respectively, regardless of treatments (Fig. 3B, top row).

MCF7-pRS or MCF7-pRS-shIGFBP5 cell–derived tumors showed positive staining for the cell proliferation marker phosphohistone-H3, which was similar in the presence or absence of tamoxifen treatment alone (Fig. 3B, second row; 3C, a versus b, d versus e). Similar levels of phosphohistone-H3 were also observed for MCF7-pRS cell–derived tumors treated with rIGFBP5 alone, but were reduced for MCF7-pRS-shIGFBP5 cell–derived tumors treated with rIGFBP5 alone (a versus c, d versus f; \( P < 0.05 \)). On the other hand, MCF7-pRS cell–derived tumors showed positive staining for the apoptosis marker cleaved caspase-3 and areas of apoptotic cells identified by TUNEL staining, which were both significantly higher with tamoxifen treatment alone than in untreated MCF7-pRS (\( P < 0.001 \) for cleaved caspase-3, \( P < 0.05 \) for TUNEL) and tamoxifen-treated MCF7-pRS-shIGFBP5 (\( P < 0.01 \) for cleaved caspase-3, \( P < 0.05 \) for TUNEL) cell–derived tumors (Fig. 3B, third and bottom rows; 3C, a versus b, b versus e), but not with rIGFBP5 treatment alone in MCF7-pRS.
cell–derived tumors (a versus c). This increase in apoptosis levels was not observed in MCF7-pIgR-shIGFBP5 cell–derived tumors treated with tamoxifen alone or rIGFBP5 alone (d versus e, d versus f) or in MCF7-pIgR cell–derived tumors. Cotreatment of MCF7-pIgR-shIGFBP5 cell–derived tumors with tamoxifen and rIGFBP5 resulted in a reduction in phosphoactin-H3–positive staining compared with treatment with tamoxifen alone (Fig. 3B, second row; 3C, e versus g; P < 0.01), but not compared with treatment with rIGFBP5 alone (f versus g). On the other hand, no changes in cleaved caspase-3 or TUNEL staining were observed (Fig. 3B, third row; 3C, e versus g, f versus g). The differential effects of endogenous IGFBP5 and exogenous rIGFBP5 on tumor growth, cell proliferation, and tamoxifen-mediated apoptosis in tamoxifen-treated tumors are due to different concentrations, sites of action (intracellular versus extracellular; ref. 11), and tamoxifen-independent and tamoxifen-dependent effects of endogenous and exogenous IGFBP5. Therefore, tamoxifen induces apoptosis in drug-sensitive ER-expressing tumors; suppression of endogenous IGFBP5 induces tamoxifen resistance due to concomitant ER loss; and exogenous rIGFBP5 cotreatment can reverse tamoxifen resistance through ER-independent mechanisms involving both tamoxifen-independent and tamoxifen-dependent components in arresting growth.

IGFBP5 expression positively correlates with tamoxifen response in breast cancer patients. The clinical relevance of our observations was examined by immunohistochemical analysis of IGFBP5 expression in human breast cancer tissue from a cohort of 153 patients treated previously with tamoxifen (Supplementary Table S2). Of the 105 cases available for analysis, 46 (44%) had low and 59 (56%) had high IGFBP5 expression (Fig. 4A). Cases with low IGFBP5 expression had a reduced mean overall survival (P = 0.008) of 63 months (95% CI, 47–79 months) compared with 101.7 months (95% CI, 83–121 months). Expression of IGFBP5 was independently associated with survival (HR, 0.45; P = 0.025) correcting for ER status (HR, 0.249; P = 0.006), lymph node status (HR, 5.4; P < 0.001), size (HR, 1.7; P < 0.001), and grade (HR, 1.44; P = 0.17). Despite our in vitro evidence showing that concomitant loss of ER expression after IGFBP5 suppression underlies tamoxifen resistance, IGFBP5 expression was not associated with grade, ER status, size, or lymph node status. However, IGFBP5 low-expressing tumors were significantly larger than high-expressing tumors (mean size, 2.77 versus 2.04 cm; P < 0.01). These data lend credence to our in vitro studies pointing to the importance of IGFBP5 in tamoxifen resistance.

Discussion

Intracellular IGFBP5 in breast cancer cells has potent anti-proliferative and proapoptotic effects (12), whereas the effects of exogenous IGFBP5 are contradictory (13–15). Exogenous IGFBP5 had no effect on IGF-I–stimulated DNA synthesis (13), protected from ceramide-induced apoptosis (14), or resensitized cells to the growth inhibitory effects of tumor necrosis factor α (15). Downregulation of IGFBP5 is associated with E2–induced growth stimulation of breast cancer cells (16). We observed tamoxifen resistance due to suppression of endogenous IGFBP5 in MCF7 cells and concomitant loss of ER expression, which could be reversed by exogenous rIGFBP5 in vitro and in vivo, through tamoxifen-independent and tamoxifen-dependent growth arrest, but not restoration of ER expression. The differential effects of exogenous and endogenous IGFBP5 on tumor growth were also due to different concentrations and sites of action (11).

IGFBP5 expression has been associated with ER status and metastasis in breast cancer (17). We found that low IGFBP5 expression was associated with shorter overall survival, providing further evidence that IGFBP5 is involved in tamoxifen resistance. Although ER status was not associated with IGFBP5 expression in the current study, this may be owing to the low proportion of ER-negative patients (7.8%) in the cohort of patients (Supplementary Table S2). Precedent comes from microarray data showing that relative IGFBP5 expression level determines tamoxifen responsiveness (18). The variegated effects of IGFBP5 could be due to differential cellular localization, IGF-I signaling pathway status, IGF-I–dependent effects, or alterations in cross talk between IGF-I and ER signaling (11, 19, 20). In conclusion, our findings reveal IGFBP5 as a potential therapeutic in managing tamoxifen resistance in breast cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Mie Konno for tissue microarray construction and database entry.

Grant Support

A postdoctoral fellowship and a graduate studentship from the Alberta Cancer Board (B.-Y. Ahn and D. Trinh, respectively), Alberta Cancer Research Institute grant 23123, Canada Institute of Health Research grant MOP97962, and Canada Research Chair Program grant 956-20751 (S.-W. Kim).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 08/19/2009; revised 01/06/2010; accepted 02/20/2010; published OnlineFirst 03/30/2010.

References


Genetic Screen Identifies Insulin-like Growth Factor Binding Protein 5 as a Modulator of Tamoxifen Resistance in Breast Cancer

Bo Young Ahn, Adam N. Elwi, Byoungchun Lee, et al.

Cancer Res 2010;70:3013-3019. Published OnlineFirst March 30, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-3108

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/03/29/0008-5472.CAN-09-3108.DC1

Cited articles
This article cites 20 articles, 6 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/8/3013.full.html#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/70/8/3013.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.